Unlock your academic potential and expand your network by joining us!

Paola Savoia

Prof. Paola Savoia

Università del Piemonte Orientale UPO, Department of HealthSciences

Share Link

Share

Information

Paola Savoia, full professor in Dermatology at the University of Eastern Piedmont, Novara, Italy, has been the head of the Clinical Section of Dermatology, at the AOU Maggiore della Carità, Novara, since 2016. She holds a Master's Degree in Medicine and Surgery (1990) and a Specialization in Dermatology and Venereology (1994) from the University of Turin, Italy. Her main fields of interest are represented by pathogenesis, diagnosis, and innovative therapeutic approaches to skin cancer. Her research is collected in 202 scientific publications in international journals with an impact factor (H-index 36; ORCID ID: 0000-0002-1636-8411) and over 250 scientific reports presented at national and international congresses. Her clinical activity includes diagnosis, treatment, and follow-up for patients with cutaneous melanoma, non-melanoma skin cancers, and primary cutaneous lymphoma.

Research Keywords & Expertise

Melanoma
Skin Cancer
immumotherapy
Skin aging
Melanoma treatment

Fingerprints

24%
Melanoma
16%
Skin Cancer
5%
Skin aging

Short Biography

Paola Savoia, full professor in Dermatology at the University of Eastern Piedmont, Novara, Italy, has been the head of the Clinical Section of Dermatology, at the AOU Maggiore della Carità, Novara, since 2016. She holds a Master's Degree in Medicine and Surgery (1990) and a Specialization in Dermatology and Venereology (1994) from the University of Turin, Italy. Her main fields of interest are represented by pathogenesis, diagnosis, and innovative therapeutic approaches to skin cancer. Her research is collected in 202 scientific publications in international journals with an impact factor (H-index 36; ORCID ID: 0000-0002-1636-8411) and over 250 scientific reports presented at national and international congresses. Her clinical activity includes diagnosis, treatment, and follow-up for patients with cutaneous melanoma, non-melanoma skin cancers, and primary cutaneous lymphoma.